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The fate of Müller’s glia following experimental retinal
detachment: nuclear migration, cell division, and subretinal glial
scar formation
Geoffrey P. Lewis, Ethan A. Chapin, Gabriel Luna, Kenneth A. Linberg, Steven K. Fisher
Neuroscience Research Institute, University of California, Santa Barbara, CA
Purpose: To study the fate of Müller’s glia following experimental retinal detachment, using a “pulse/chase” paradigm
of bromodeoxyuridine (BrdU) labeling for the purpose of understanding the role of Müller cell division in subretinal scar
formation.
Methods: Experimental retinal detachments were created in pigmented rabbit eyes, and 3 days later 10 µg of BrdU was
injected intravitreally. The retinas were harvested 4 h after the BrdU was administered (i.e., day 3) or on days 4, 7, and
21 post detachment. The tissue was fixed, embedded in agarose, and sectioned at 100 µm. The sections were labeled with
various combinations of probes, including anti-vimentin and anti-S100 (as markers for Müller cells), anti-BrdU, anti-
phosphohistone H3 (to identify mitotic cells), and the isolectin B4 (to identify macrophages and microglia). Images were
captured using an Olympus Fluoview 500 confocal microscope. To aid in our understanding of how Müller cell nuclei
undergo cell division, two additional procedures were used: 1) electron microscopy of normal cat and rabbit retinas and
2) a new method using 5-fluorouracil and subsequent anti-BrdU labeling to detect all Müller cell nuclei, using confocal
imaging.
Results: Three days after detachment, anti-vimentin labeled all Müller cells, some of which were also labeled with anti-
BrdU. On day 4, many of the anti-BrdU-labeled Müller cell nuclei appeared in columns with one labeled nucleus in the
inner nuclear layer and another directly sclerad to it in the outer nuclear layer. By day 7, most anti-BrdU-labeled nuclei
were observed in subretinal scars. At 3 weeks, some anti-BrdU-labeled nuclei that remained within the retina did not
express vimentin or S100. Anti-phosphohistone H3-labeled (i.e., mitotic) cells, some of which were also labeled with anti-
BrdU, were only observed in the outer nuclear layer on day 4, and these nuclei were surrounded by an accumulation of
vimentin  filaments.  Isolectin  B4-labeled  microglia  and  macrophages  also  incorporated  BrdU  and  were  observed
throughout the retina and in subretinal scars during all times of detachment. Electron microscopy and immunofluorescence
labeling of the 5-fluorouracil-injected eyes revealed the presence of a unique structural relationship between Müller cell
nuclei and intermediate filament proteins.
Conclusions: Following retinal detachment, many Müller cell nuclei initially migrate to the outer retina, undergo mitosis,
and eventually reside in subretinal glial scars, suggesting a possible link between the early division of Müller cells and
the process of subretinal gliosis. In addition, a subpopulation of anti-BrdU-labeled cells, presumably once Müller cells,
appears to stop expressing well accepted Müller cell marker proteins, suggesting a potential dedifferentiation of some of
these cells over time. Additionally, Müller cell nuclei may use intermediate filaments as a “track” for migration into the
outer retina and later as an important component of cell division by the accumulation of vimentin filaments around the
mitotic nuclei.
Injury to the retina, as elsewhere in the central nervous
system (CNS), results in the activation of glial cells and the
formation of glial scars [1,2]. In retinal detachment (RD), a
form of traumatic injury where the retina becomes separated
from the underlying retinal pigment epithelial (RPE) layer, the
Müller  cell,  generally  considered  a  specialized  radial
astrocyte,  is  the  predominant  glial  cell  type  involved.
Following  RD,  Müller  cells  actively  proliferate  and
hypertrophy within the retina and onto either retinal surface
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where they form structures similar to those formed by reactive
astrocytes in the brain and spinal cord [3]. Such cellular scars
or  “membranes”  present  on  the  subretinal  or  epiretinal
(vitreal)  surface  are  considered  part  of  the  spectrum  of
“fibrocontractive  retinal  disorder”  termed  proliferative
vitreoretinopathy (PVR) [4]. Despite numerous attempts to
reduce the incidence of PVR, no effective pharmacological
treatment has been found to date [5,6]. This may be because
PVR is a complex disease involving cell proliferation, growth,
spreading,  and  contractility.  Dividing  cells  have  been
observed in membranes removed from patients with PVR
([7–9]  and  unpublished  data);  however,  data  from  animal
models as well as from membranes removed from human
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1361patients clearly show a role for Müller cell expansion as a
critical part of the response.
Müller  cell  reactivity  can  ultimately  result  in  loss  of
vision because of glial scars on the retinal surfaces. When
scars are present in the subretinal space, the regeneration of
photoreceptor outer segments is prevented [10]. Subretinal
glial  scars  can  also  cause  visual  distortion  by  preventing
proper flattening of the retina or causing macular wrinkling,
both of which may require surgical removal of the scar tissue
[11]. This is not an insignificant problem since subretinal glial
scars in humans have been estimated to occur in 15.7% of all
human retinal detachments [12]. When a glial scar grows on
the vitreal surface of the retina, the cells can contract, causing
retinal folds and re-detachment of the retina. Indeed, epiretinal
membrane formation and subsequent contraction detachment
remains  the  most  common  reason  for  failure  of  retinal
reattachment surgery and occurs in 5%–12% of cases [13–
17].  Although  advances  in  surgical  management  have
improved the ability to ultimately reattach the retina after the
occurrence of a contraction detachment, the visual prognosis
remains poor, with only 11%–25% of patients achieving a
visual acuity of 20/100 [18]. Glial scar formation, therefore,
is a serious complication of retinal injury. However, the early
events in scar formation are poorly understood.
PVR is generally thought to be a condition involving
uncontrolled  cell  proliferation,  although  the  exact  role  of
proliferation and how it relates to the hypertrophy of Müller
cells and ultimate glial scar formation in the injured retina is
unclear. It has been demonstrated that within a few hours of
detachment,  Müller  cells  upregulate  transcription  factors
related to both proliferation and hypertrophy [19], and at one
day after detachment, both events are underway, as evidenced
by anti-Ki67 and anti-glial fibrillary acidic protein (GFAP)
labeling, respectively [20,21]. Proliferation peaks 3–4 days
after detachment, is reduced at day 7, but continues at low
levels for as long as the retina remains detached [22,23].
Hypertrophy and growth of Müller cells into the subretinal
space also appear to occur as an ongoing event since longer
detachment durations result in larger subretinal glial scars.
The question remains, however, as to the role, if any,
cellular proliferation has in the formation of glial scars. That
is, are glial scars formed only by the population of cells that
proliferate? Use of the anti-proliferative agent 5-fluorouracil
(5-FU) did not significantly reduce the occurrence of PVR in
human patients [6], although issues of timing and dosage
make these results difficult to interpret. Moreover, the process
of cell division of Müller cells, complex cells that span the
entire  width  of  the  retina,  has  not  been  elucidated  in  the
mammalian  retina.  To  address  these  issues,  we  used  an
intraocular pulse of bromodeoxyuridine (BrdU), given at the
peak of the proliferative response after retinal detachment in
the rabbit, and followed the distribution of the labeled nuclei
over time. We show here that the Müller cell nuclei that
incorporate BrdU on day 3 appear to migrate into the outer
retina where they undergo mitosis. Some Müller cells with
anti-BrdU-labeled nuclei then grow beyond the outer limiting
membrane (OLM) to begin the process of glial scar formation.
The glial scars expand with increasing detachment time, and
many anti-BrdU-labeled nuclei come to reside in the scars.
These  data  suggest  a  significant  role  for  Müller  cell
proliferation,  beginning  early  after  detachment,  in
contributing  to  the  formation  of  subretinal  glial  scars.  In
addition,  immunocytochemical  observations  of  anti-GFAP
and anti-vimentin labeling along with electron microscopic
data suggest a link between the migration of Müller cell nuclei
and the intermediate filament cytoskeleton.
METHODS
Retinal  detachment  surgery:  Retinal  detachments  were
created  in  adult  New  Zealand  Red  pigmented  rabbits
(Myrtle’s Rabbitry, Thompsons Station, TN) by infusing a
solution of sodium hyaluronate (Healon, 0.25% in balanced
salt solution; Pharmacia, Piscataway, NJ) between the neural
retina  and  RPE  via  a  fine  glass  pipette.  The  Healon  is
necessary to prevent spontaneous reattachment of the retina.
The pipette was inserted into the eye via an incision that was
made several millimeters below the pars plana to prevent the
pipette from touching the lens. Approximately one-half of the
inferior  retina  was  detached  in  the  right  eye,  leaving  the
superior attached regions as internal controls. The left eyes
served as non-detached controls. On day 3 after detachment,
the eyes were injected with 10 µg BrdU (Sigma, St Louis, MO)
in 50 µl balanced salt solution (BSS; Alcon, Ft. Worth, TX).
Animals were euthanized either 4 h after the BrdU injection
on day 3, or on days 4, 7, or 21 post detachment, using sodium
pentobarbital (120 mg/ml, IV). Three animals were used at
each time point. Following enucleation, the eye was fixed in
4% paraformaldehyde for at least 24 h (in 0.1 M sodium
cacodylate buffer, pH 7.4; Electron Microscopy Sciences,
Fort Washington, PA) and stored until used. All experimental
procedures conformed to the ARVO statement for the Use of
Animals in Ophthalmic and Vision Research, the Guide for
the Care and Use of Laboratory Animals, and the guidelines
of the Animal Resource Center of the University of California,
Santa Barbara.
Immunocytochemistry: Following at least 24 h of fixation,
retinal pieces approximately 4 mm square, were excised from
three detached regions within each eye. The tissue was rinsed
in PBS (10X PBS stock: 250 mls distilled water, 21.92 g NaCl,
0.67 g NaH2PO4, 2.88 g NaH2PO4; stir well, dilute 1:10 in
distilled  water,  adjust  pH  to  7.4.  Yields  0.086M  PBS),
embedded in low-melt agarose (5%; Sigma), and sectioned at
100 µm using a vibratome (Technical Products International,
Polysciences, Warrington, PA). Sections were incubated in
normal donkey serum (1:20) in PBS, 0.5% BSA, 0.1% Triton
X-100, and 0.1% azide (PBS, BSA [PBTA]) overnight at 4 °C
on a rotator. The following day the sections were pretreated
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1362Figure 1. Laser scanning confocal images of control (A) and detached (B-F) rabbit retinas labeled with anti- bromodeoxyuridine (BrdU; red),
anti-vimentin (green), and isolectin B4 (blue). BrdU was injected intravitreally on day 3. In control retina (A; 4 h after BrdU injection into
the normal eye), no BrdU is detected and anti-vimentin labeling of Müller cells extends from their endfeet into the outer nuclear layer (ONL).
At 3 days after detachment (4 h after intravitreal injection of BrdU), anti-BrdU labeling is present in many Müller cell nuclei in the inner
nuclear layer (INL), and anti-vimentin labeling in Müller cells spans the entire width of the retina. At 4 days after detachment (24 h after BrdU
injection), BrdU-labeled nuclei frequently appear in radial columns across the retina (C, arrows). In some cases, two nuclei can be observed
directly adjacent to one another (D, arrows). Anti-BrdU-labeled nuclei are also observed directly adjacent to anti-vimentin-labeled Müller cell
processes extending into the subretinal space (E, brackets). At 7 days after detachment, many anti-BrdU-labeled Müller cells are observed in
large subretinal glial scars that are also labeled with anti-vimentin (F, brackets). The isolectin B4 labels the stellate processes of the microglia
in the inner plexiform layer (IPL) in the control retina (A), but after detachment these cells round-up and migrate throughout the retina and
into subretinal glial scars (B-F). The isolectin B4 also labels macrophages in the subretinal space (B-F). Some macrophages (in the subretinal
space) and microglia (in the retina) are labeled with anti-BrdU (D, E, F, arrowheads). Abbreviations: GCL represents ganglion cell layer;
OLM represents outer limiting membrane. Scale bars are equal to 50 µm.
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1363with 2 N HCL for 1 h as an antigen retrieval step for the BrdU.
After rinsing in PBTA, the primary antibodies and lectin were
added and incubated overnight at 4 °C on a rotator in PBTA.
Anti-BrdU (1:200; Accurate Chemical and Scientific Corp.,
Westbury, NY) was used to detect cells in S-phase; anti-
phosphohistone H3 (1:100; Lake Placid, NY) was used to
detect cells undergoing mitosis; anti-vimentin (1:500; Dako,
Carpinteria, CA) and anti-S100 (1:1000; Dako) were used to
identify  Müller  cells;  and  isolectin  B4,  Griffonia
simplicifolia (1:50; Vector Labs, Burlingame, CA), was used
to label microglia and macrophages. Following rinsing of the
primary  antibodies  in  PBTA,  the  secondary  probes
(streptavidin  CY5,  donkey  antirat  CY3,  and  donkey
antimouse CY2; Jackson ImmunoResearch, West Grove, PA)
were added together, each at 1:200 in PBTA, overnight at 4 °C
on a rotator. On the final day, the sections were rinsed in
PBTA, mounted on glass slides, using 5% n-propyl gallate in
glycerol,  and  viewed  on  an  Olympus  Fluoview  500  laser
scanning  confocal  microscope  (Center  Valley,  PA).  Each
image represents a projection from a z-stack of 6–10 images
collected at 0.5-µm increments.
Müller cell nuclei and the cytoskeleton: To systematically
study the relationship between intermediate filaments and
Müller cell nuclei, we took advantage of the observation that
Müller cells appear to specifically take-up 5-FU, which can
then be detected with anti-BrdU. Since uracil is normally
converted to uridine by cells, presumably the same process
occurs with 5-FU after injection into the vitreous, and the
product is then detected by anti-BrdU. Why this appears to
preferentially label Müller cells remains a mystery but may
be related to Müller cells’ close apposition to the vitreous
cavity, the site of 5-FU deposition. In this experiment, 5-FU
(0.5  mg  in  50-µl  balanced  salt  solution)  was  injected
intravitreally into “normal” rabbit eyes (n=3). Three days later
animals were euthanized (120 mg/kg Euthasol, intravenous,
Henry Schein, Melville, NY), and the eyes fixed as described
above. The retinas were then sectioned and labeled with anti-
BrdU  as  well  as  anti-  GFAP  (1:400;  Dako)  and/or  anti-
vimentin (1:500; Dako), as described below.
Electron microscopy of archived cat and rabbit tissue was
also examined to study the ultrastructure of Müller cell nuclei.
Both  nondetached  cat  and  rabbit  retinas  and  cat  retinas
detached for 50 days were fixed in 1% glutaraldehyde plus
1% paraformaldehyde for 24 h after which the tissue was
rinsed in isotonic phosphate buffer, postfixed for 2 h in 2%
osmium tetroxide in phosphate buffer, dehydrated in a graded
ethanol  series,  processed  through  propylene  oxide,  and
embedded in Spurr’s resin. The retinas were then sectioned at
90  nm  in  thickness,  stained  with  uranyl  acetate  and  lead
citrate, and viewed using a JEOL 1230 electron microscope.
RESULTS
Fate of injected bromodeoxyuridine: In control nondetached
rabbit  retinas,  anti-vimentin  labeling  of  the  Müller  cells
extends from the inner limiting membrane (ILM) into the
outer  nuclear  layer  (ONL;  Figure  1A,  green).  Based  on
previous data showing that intraretinal proliferation peaks at
3 days in the rabbit [20], BrdU was injected into the vitreous
at this time and the tissue examined 4 h later. At this time
point,  anti-vimentin  labeling  increased,  filling  the  entire
Müller cell from the ILM to the OLM (Figure 1B). Numerous
anti-BrdU-labeled Müller cell nuclei could also be seen in the
inner nuclear layer (INL; Figure 1B, red). At day 4, 24 h after
BrdU injection, labeled nuclei frequently appeared in radial
“columns” across the retina, such that one labeled nucleus in
the ONL directly overlies another in the INL (Figure 1C,
arrows). In some cases two nuclei could be observed directly
adjacent to one another, always in a “vertical” arrangement,
giving the impression that they occur in the same Müller cell
(Figure 1D, arrows). We never observed two labeled nuclei
lying “side-by-side” in the INL. Also at the 4-day detachment
time, the first sign of Müller cell growth beyond the OLM into
the  subretinal  space  was  observed  (Figure  1E,  bracket).
Invariably, there was an anti-BrdU-labeled nucleus associated
with this early stage of growth, itself often appearing to extend
partially beyond the OLM. At 7 days following detachment,
many  anti-BrdU-labeled  nuclei  were  present  within,  or
adjacent to, large subretinal glial scars (Figure 1F, brackets),
although in regions away from the scars, the retina appeared
mostly devoid of labeled nuclei (Figure 1F, left half of the
image).  Subretinal  scars,  however,  were  never  observed
without containing anti-BrdU-labeled nuclei.
Microglia and macrophages also undergo cell division in
the retina after detachment [22]. To ascertain that the majority
of BrdU labeling was occurring in Müller cells, we used the
isolectin  B4  to  identify  the  former  cell  types.  As  shown
previously, the cells within the retina are primarily resident
microglia, whereas those in the subretinal space are mostly
macrophages that have entered the eye from the blood [24].
Isolectin B4-labeled microglia in attached regions from an eye
with a retinal detachment appear as an array of fine stellate
processes  confined  primarily  to  the  inner  plexiform  layer
(IPL; Figure 1A, blue). Following detachment, the microglia
round-up  and  migrate  into  the  outer  retina,  whereas
macrophages appear to remain in the subretinal space (Figure
1B-F;  also  see  ref.  #26,  for  quantitative  data).  Some
macrophages (in the subretinal space) and microglia (in the
retina) can be observed labeled with anti-BrdU (Figure 1D-F,
arrowheads). In comparison to Müller cells, the number of
anti-BrdU-labeled  immune  cells  is  very  low  (Figure  1D).
That, combined with the prominent anti-vimentin labeling of
Müller cells makes their confusion unlikely. Some retinal
regions were relatively devoid of immune cells, while others
contained  many,  but  there  was  no  apparent  correlation
between the presence of these cells and the extent of glial scar
formation.
The columnar pattern of BrdU-labeled nuclei across the
retina suggests that both nuclei at this stage occur within the
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1364same Müller cell, although it is difficult to be certain from the
confocal two-dimensional projection images in Figure 1 (C-
E).  However,  by  processing  the  z-stack  of  images  using
bioView software (version 1.1.18, free download from the
Center for bio-image informatics, UCSB, Santa Barbara, CA)
to provide varying contrasts, it appears likely that the vertical
pairs of BrdU-labeled nuclei are indeed associated with a
single Müller cell “stalk” of intermediate filaments (Figure
2A,B). Figure 2A shows a pair of nuclei lined up directly along
one distinct column of intermediate filaments, presumably
within a single Müller cell, whereas the image in Figure 2B is
rotated slightly so that the lower nucleus in the INL appears
off to the side of the major intermediate filament bundle.
Twenty-one days after detachment, many of the anti-
BrdU-labeled nuclei in regions away from a subretinal scar
appeared  unassociated  with  anti-vimentin-labeled  cells
(Figure  3A-D,  arrows;  day  21),  especially  when  viewed
through the z-series of images. Some of the nuclei could also
be observed in the ganglion cell layer (GCL) at this time
(Figure 3C). Vimentin, however, is a cytoskeletal protein and
hence does not necessarily fill the entire cell. Therefore, anti-
S100,  a  calcium-binding  protein,  was  used  to  label  the
cytoplasm of Müller cells. Since anti-S100 labels the entire
cytoplasm with heavy labeling of the cell body, any anti-
BrdU-labeled nuclei in S100 positive cells should reflect the
overlay  of  the  two  fluorochromes  (in  this  case,  red
+blue=pink). Interestingly, many BrdU-labeled nuclei do not
appear to lie within anti-S100-labeled cells (Figure 3A-D,
arrows), i.e., the nuclei appear red with no overlying blue or
green  labeling.  By  turning  off  the  BrdU  (red)  channel,  it
Figure 2. Laser scanning confocal images of rabbit retinas detached for 4 days labeled with anti-bromodeoxyuridine (BrdU; red) and anti-
vimentin (green). The z-stack of images is projected in three dimensions at varying contrasts, illustrating that the BrdU-labeled nuclei appear
to be associated with only one Müller cell process. A shows two nuclei lined up directly with a single Müller cell “stalk” of intermediate
filaments (arrows). The image in B is rotated slightly so that the lower nucleus in the INL appears off to the side of the major intermediate
filament bundle. Abbreviations: GCL represents ganglion cell layer; IPL represents inner plexiform layer; INL represents inner nuclear layer;
ONL represents outer nuclear layer; OLM represents outer limiting membrane. The scale bar is equal to 20 µm.
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1365became apparent that there was little to no S100 or vimentin
in  the  cells  associated  with  this  subpopulation  of  BrdU-
positive nuclei, although they always lie adjacent to areas of
heavy  anti-S100  or  anti-vimentin  labeling  (Figure  3B,D,
arrows). In an area where the band of intermediate filaments
overlays the nucleus of a BrdU- and S100-positive cell, the
resulting triple labeling produces a white signal (Figure 3A;
arrowhead).
To determine if Müller cells were undergoing mitosis in
addition to undergoing DNA synthesis in S phase, we labeled
sections with both anti-phosphohistone H3 (green) and anti-
BrdU (red) at all detachment time points (Figure 4). Many
Figure 3. Laser scanning confocal images of rabbit retinas detached for 3 weeks and labeled with anti-bromodeoxyuridine (BrdU; red), anti-
vimentin (green), and anti-S100 (blue). BrdU was injected intravitreally on day 3. Many anti-BrdU-labeled nuclei are present throughout the
retina, some of which are co-labeled with anti-S100, giving them a purple appearance, while many others do not label with anti-S100 and
appear red (arrows). The areas labeled with all three antibodies appear white (A, arrowhead). The images in B and D are the same images as
A and C without the red (anti-BrdU) channel. Abbreviations: GCL represents ganglion cell layer; INL represents inner nuclear layer; ONL
represents outer nuclear layer. The scale bars are equal to 50 µm.
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1366anti-phosphohistone H3-labeled cells were observed, but only
at the 4-day time point. Some of these cells were also double
labeled with anti-BrdU (Figure 4A,B; insets have the red
BrdU channel turned off). Significantly, while anti-BrdU-
labeled  cells  were  observed  throughout  the  retina,  anti-
phosphohistone  H3-labeled  mitotic  figures  were  observed
only  in  the  ONL,  suggesting  that  Müller  cell  nuclei
incorporate BrdU in the INL before migrating to the ONL to
divide. The fact that anti-phosphohistone H3-labeled mitotic
figures were observed only at 4 days suggests that most of the
cell division occurs as a single “wave” within a few days
following detachment. Additionally, the anti-phosphohistone
H3-labeled  cells  often  appear  surrounded  by  dense  anti-
vimentin  labeling,  presumably  representing  a  localized
accumulation of intermediate filaments (Figure 4A,C,D, blue,
arrows).  To  appreciate  that  this  “cage”  of  intermediate
Figure 4. Laser scanning confocal images of rabbit retinas detached for 4 days and labeled with anti-bromodeoxyuridine (BrdU; red), anti-
phosphohistone H3 (green), and anti-vimentin (blue). BrdU was injected intravitreally on day 3. Anti-phosphohistone H3 labeling of mitotic
cells is only observed in the outer nuclear layer (ONL). Some, but not all, of the anti-phosphohistone H3-labeled cells are also labeled with
anti-BrdU (A, B). The insets in A and B are cropped from the same image but without the red BrdU channel to more easily visualize the
phosphohistone H3 labeling (long arrows point to the same nucleus without the BrdU labeling). Many of the anti-phosphohistone H3-labeled
nuclei are surrounded by an accumulation of vimentin filaments (A, C, D, short arrows). Figures C and D are the same image but digitally
rotated by tilting the z-stack in different directions to reveal the three-dimensional architecture of the vimentin filaments around the mitotic
cell. The top and bottom images of the z-stack were omitted to visualize the anti-phosphohistone H3 labeling within this region. Abbreviations:
INL represents inner nuclear layer; IPL represents inner plexiform layer; GCL represents ganglion cell layer, OLM represents the outer limiting
membrane, ONL represents the outer nuclear layer. Scale bars are equal to 50 µm (A, B) or 20 µm (C, D).
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1367filaments completely envelops the mitotic figure formed as
the cell divides, Figure 4C,D shows one image tilted slightly
in two different directions (anti-phosphohistone H3, green,
arrow; anti-vimentin, blue). The top and bottom images of the
z-stack  were  omitted  to  avoid  obscuring  the  anti-
phosphohistone  H3  labeling  within  the  cage  of  vimentin
filaments.
Structural mechanism for nuclear migration: Since mitotic
Müller cells were only observed in the ONL we sought a
possible mechanism to explain nuclear migration into the
outer retina. In many of the images labeled with anti-BrdU
and  anti-vimentin,  we  observed  what  appeared  to  be  a
narrowing of the band of intermediate filaments and their
apparent association with a “groove” or “notch” in the Müller
cell nucleus (Figure 5A,B). Electron microscopy of tissue
from both rabbit and cat retinas clearly demonstrate the deep
indentation  of  the  Müller  cell  nuclei  and  the  presence  of
intermediate  filaments  within  the  notch  formed  by  the
indentation (Figure 5C,D, arrows). The prevalence of this
nuclear notch and its relationship to the intermediate filament
cytoskeleton is demonstrated by confocal imagining of tissue
from normal (nondetached) rabbit retinas that had been treated
with 5-FU and labeled with anti-BrdU to visualize all Müller
cell  nuclei.  In  both  radial  sections  (Figure  6A,B)  and
wholemount preparations (Figure 6C-F), the notch can be
clearly observed in every Müller cell nucleus (red labeling)
within  a  field.  In  addition,  vimentin  filaments  (green)
invariably localize on the side of the cell facing the notch and
in many instances can be seen to fill the notch itself. While
anti-GFAP labeling also localized to this region (Figure 6C,D,
blue),  unlike  vimentin  filaments,  GFAP  filaments  are  not
present in all the nuclei in the nondetached retina. When
present, however, they too bundle with vimentin at the site of
the notch.
DISCUSSION
The original goal of this study was to determine if Müller cell
proliferation is an important mechanism in the formation of
subretinal  glial  scars.  The  data,  however,  provide  new
information about the reactivity of these highly differentiated
glial  cells  as  well  as  suggest  a  specific  role  for  their
proliferation in glial scar formation. BrdU, injected into the
vitreous at the height of the proliferative response following
detachment, provided a means to follow the fate of the labeled
nuclei  over  time.  Our  interpretation  of  the  results  is
summarized in Figure 7 showing a Müller cell nucleus with
its unique structural relationship to the cells’ intermediate
filament cytoskeleton (based on the image in Figure 5A).
Within 24 h after BrdU injection, anti-BrdU-labeled Müller
cell  nuclei  migrate  along  the  intermediate  filament
cytoskeleton to the outer retina (Figure 7, step 1). Once there,
Figure 5. Three images illustrating the indentation or “notch” within a single Muller cell nucleus. A, B: Laser scanning confocal images of
rabbit retina detached for 3 days and labeled with both anti-bromodeoxyuridine (BrdU; red) and anti-vimentin (green). B is the same image
as shown in A, with the two colors separated to better visualize the vimentin filaments (green) and the notch in the (single) nucleus (red, inset).
C, D: Electron micrographs of normal rabbit (C) and 50-day detached cat (D) retinas showing a notch within Muller cell nuclei (arrows). Note
the Müller cell nucleus in D now resides among the dark photoreceptor nuclei after detachment. Abbreviations: ONL represents outer nuclear
layer; INL represents inner nuclear layer; GCL represents ganglion cell layer. Scale bars equal to 10 µm A, B; 5 µm C, D.
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1368Figure 6. Laser scanning confocal images of radial sections (A, B) and wholemounts (C- F) of control rabbit retina labeled with anti-
bromodeoxyuridine (BrdU; red), anti-vimentin (green), and anti-glial fibrillary acidic protein (GFAP; blue) from eyes injected with 5-
fluorouracil (5-FU). The anti-BrdU detects the 5-FU, which is present in all Müller cell nuclei and illustrates that the notch is visible in most
of them (A-F). In addition, GFAP filaments are present in only some of the notches (C, D), while vimentin filaments appear to be present in
all of the notches (E, F). The images in the right panels are the same as those on the left but illustrate only the BrdU labeling. The insets in
B are higher magnifications of the regions marked with the brackets to more easily visualize the notch (arrows). Abbreviations: GCL represents
ganglion cell layer; INL represents inner nuclear layer; ONL represents outer nuclear layer. The scale bars are equal to 20 µm.
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1369vimentin filaments assemble around the nucleus, which then
undergoes mitosis, as indicated by the anti-phosphohistone
H3-labeling  data  (Figure  7,  step  2).  Assuming  that  every
BrdU-labeled Müller cell nucleus undergoes division in the
outer  retina  and  based  on  the  columnar  pattern  observed
frequently at day 4, the parent Müller cell may occur in a
binucleate phase for a short time, about the same time Müller
cells begin to grow processes into the subretinal space. Some
of  these  cells  may  remain  binucleate,  with  one  nucleus
returning to its normal location in the INL (Figure 7, step 3)
and the other nucleus migrating into the processes forming the
subretinal scar (Figure 7, steps 4 and 5). Other Müller cells
seem to bud off, forming a daughter cell containing one of the
nuclei but not labeling with such typical Müller cell markers
as anti-vimentin or anti-S100, as if they occur in some stage
of dedifferentiation (Figure 7, step 6). Taken together, these
data suggest that early Müller cell proliferation is in some way
mechanistically coupled to the eventual formation of large
subretinal glial scars.
Overall, our observations are remarkably similar to those
observed in the injured zebrafish retina [25], although the final
outcome is probably very different. Following light damage
to the fish retina, which destroys the photoreceptors, Müller
cell nuclei migrate to the outer retina where they re-enter the
cell cycle. The daughter cell in this case, however, buds off
from the parent Müller cell and becomes a retinal progenitor
cell,  as  evidenced  by  Pax6  expression,  which  can
dedifferentiate and eventually replace lost photoreceptors. A
similar phenomenon has also been shown in the chicken retina
in response to damage or exogenous growth factors [26]. In
Figure 7. Drawing of a Müller cell with its nucleus and vimentin cytoskeleton showing the proposed hypothesis of how these cells may undergo
nuclear division following retinal injury. Step 1, after retinal detachment the nucleus migrates to the outer nuclear layer (ONL); Step 2, vimentin
filaments accumulate around the nucleus after which the nucleus undergoes mitosis; Step 3, one nucleus migrates back to the inner nuclear
layer (INL); Step 4, the nucleus remaining in the ONL either moves to the subretinal space and contributes to the formation of a glial scar
(Step 5) or remains in the retina as a de-differentiated cell (Step 6).
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1370this  case  Müller  cells  dedifferentiate,  proliferate,  begin
expressing transcription factors normally found in embryonic
retinal progenitors, and produce both neurons and glial cells.
In the detached rabbit retina, however, we have no evidence
that cells in the subretinal space are anything other than Müller
cells since they label with typical Müller cell markers. While
we have yet to successfully label the BrdU-labeled nuclei that
appear in the outer retina with typical markers to progenitor
cells as shown in the chicken retina [26], the availability of
new progenitor cell markers suitable for use in the mammalian
retina in the future will allow addressing this issue.
The  observation  of  a  special  structural  relationship
between  Müller  cell  nuclei  and  the  intermediate  filament
cytoskeleton is also of interest. The observations are certainly
suggestive that intermediate filaments may anchor the nuclei
in place in the normal retina, provide a “track” along which
they migrate in the injured retina, and provide a means of
isolating the nuclei in a cage-like structure in the outer retina
during  mitosis.  A  similar  relationship  has  been  observed
between  migrating  pigment  granules  and  the  vimentin
cytoskeleton in Xenopus melanocytes [27]. It is possible that
this cage of filaments isolates the nucleus from the cell and
allows for nuclear division without the need for the entire cell
to round-up since we found no evidence that these cells retract
their inner processes during division.
Some BrdU-labeled nuclei observed here also occur in
cells known to participate in other reactions to detachment.
For example, a few labeled Müller cell nuclei were observed
near the vitreal border in longer term detachments (e.g., 21
days; Figures 3C), and it may be the Müller cells associated
with  these  nuclei  that  ultimately  contribute  to  epiretinal
membranes on the vitreal surface of the retina. In addition,
since there are no astrocytes in this region of the rabbit retina
(i.e., distant from the medullary rays), the only other cell types
that incorporate BrdU are the microglia and macrophages. The
robust labeling of these cells with anti-BrdU is more evidence
for a significant inflammatory response to retinal detachment
[28–30], and while they have been shown to migrate to the
photoreceptor layer after detachment [24], their role if any in
glial scar formation is unclear.
The  data  presented  here  suggest  that  Müller  cell
proliferation is a critical step for the formation of glial scars
in the retina and that an essential trigger for this scar formation
takes place during the period of early proliferation that occurs
within a few days of the injury. Clinical trials using anti-
proliferative drugs to prevent proliferative diseases in the eye
have not proven successful; however, this may be due to the
timing of treatment since these drugs are typically given only
for a short time during the surgical removal of scar tissue that
has already formed, that is, late in the disease state. Anti-
proliferative drugs used in prior clinical studies also tend to
have a very short half-life in the eye. Two separate studies in
this animal model, however, have recently demonstrated that
the  intravitreal  administration,  at  the  time  of  detachment
surgery, of two compounds with a relatively long half-life in
the eye effectively reduce both intraretinal proliferation and
the formation of subretinal glial scars [31,32]. Those studies
support  the  data  presented  in  this  paper  that  Müller  cell
proliferation, initiated within a few days after detachment, is
critical to the formation of subretinal glial scars.
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